Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Multi-center, Phase Ⅲ Clinical Study to Investigate Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection Toripalimab (JS001) Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma

Next Previous
Trial Profile

A Randomized, Controlled, Multi-center, Phase Ⅲ Clinical Study to Investigate Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection Toripalimab (JS001) Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 21 Oct 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 21 Oct 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jun 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top